Selank: Research Status, Identity, and Clinical Trial Data

Regulatory status

Selank has no FDA-approved label and is classified as an unapproved research compound. No indications, dosing, or safety information have been established through an approved drug label.

What selank is

Selank is a synthetic peptide identified in chemical databases under PubChem CID 11765600. Because no FDA label exists for this compound, its mechanism of action and pharmacological class have not been officially defined by regulatory review.

Trial footprint

Public registries list 10 registered trials associated with selank. Some entries associated with this compound in trial databases involve unrelated interventions, such as a completed phase 3 study of brivaracetam in adults with partial onset seizures and a similarly completed brivaracetam add-on trial in adolescents and adults with epilepsy. A separate completed study examined cognitive effects of acute high-altitude hypoxia exposure in lowlanders, without a listed phase. These entries illustrate the type of research infrastructure tracked for this compound rather than evidence specific to selank's effects.